Jim Fong

Corporate Officer/Principal at CTI BIOPHARMA CORP.

62 year

Health Technology

Consumer Services

Profile

Jim Fong is currently the Chief Commercial Officer & Executive VP at CTI BioPharma Corp.
He previously worked as the Director-National Sales at CV Therapeutics, Inc. Mr. Fong completed his undergraduate degree at the University of California, Los Angeles.

Jim Fong active positions

Companies	Position	Start
CTI BIOPHARMA CORP.	Corporate Officer/Principal	2007-12-31

All active positions of Jim Fong

Former positions of Jim Fong

Companies	Position	End
CV Therapeutics, Inc. CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases	Sales & Marketing	-

See the detail of Jim Fong's experience

Training of Jim Fong

University of California, Los Angeles

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Jim Fong's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
CTI BioPharma Corp. CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.	Health Technology
CV Therapeutics, Inc. CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases	Health Technology